このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

WuXi Biologics (Cayman) マネジメント

マネジメント基準チェック /14

WuXi Biologics (Cayman)'sの CEO はChris Chenで、 Jan2016年に任命され、の在任期間は 8.42年です。の年間総報酬はCN¥ 96.91Mで、 4.1%給与と95.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.35%を直接所有しており、その価値は€ 20.03M 。経営陣と取締役会の平均在任期間はそれぞれ1.8年と6.8年です。

主要情報

Chris Chen

最高経営責任者

CN¥96.9m

報酬総額

CEO給与比率	4.1%
CEO在任期間	8.4yrs
CEOの所有権	0.3%
経営陣の平均在職期間	1.8yrs
取締役会の平均在任期間	6.8yrs

経営陣の近況

Recent updates

CEO報酬分析

WuXi Biologics (Cayman) の収益と比較して、Chris Chen の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Dec 31 2023	CN¥97m	CN¥4m	CN¥3b
Sep 30 2023	n/a	n/a	CN¥4b
Jun 30 2023	n/a	n/a	CN¥4b
Mar 31 2023	n/a	n/a	CN¥4b
Dec 31 2022	CN¥79m	CN¥3m	CN¥4b
Sep 30 2022	n/a	n/a	CN¥4b
Jun 30 2022	n/a	n/a	CN¥4b
Mar 31 2022	n/a	n/a	CN¥4b
Dec 31 2021	CN¥51m	CN¥3m	CN¥3b
Sep 30 2021	n/a	n/a	CN¥3b
Jun 30 2021	n/a	n/a	CN¥3b
Mar 31 2021	n/a	n/a	CN¥2b
Dec 31 2020	CN¥31m	CN¥3m	CN¥2b
Sep 30 2020	n/a	n/a	CN¥1b
Jun 30 2020	n/a	n/a	CN¥1b
Mar 31 2020	n/a	n/a	CN¥1b
Dec 31 2019	CN¥25m	CN¥3m	CN¥1b
Sep 30 2019	n/a	n/a	CN¥922m
Jun 30 2019	n/a	n/a	CN¥831m
Mar 31 2019	n/a	n/a	CN¥731m
Dec 31 2018	CN¥20m	CN¥2m	CN¥631m
Sep 30 2018	n/a	n/a	CN¥520m
Jun 30 2018	n/a	n/a	CN¥410m
Mar 31 2018	n/a	n/a	CN¥331m
Dec 31 2017	CN¥24m	CN¥2m	CN¥253m

報酬と市場: Chrisの総報酬 ($USD 13.36M ) は、 German市場 ($USD 3.35M ) の同規模の企業の平均を上回っています。

報酬と収益: Chrisの報酬は 20% 以上増加しましたが、会社の収益は過去 1 年間で 20% 以上減少しました。

CEO（最高経営責任者

Chris Chen (51 yo)

8.4yrs

在職期間

CN¥96,911,000

報酬

Dr. Zhisheng Chen, also known as Chris, Ph.D. has been the Chief Executive Officer & Executive Director at WuXi Biologics (Cayman) Inc. since January 01, 2016 and since February 27, 2014 respectively. Dr....

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Ge Li	Founder & Chairman	10.3yrs	データなし	データなし
Zhisheng Chen	CEO & Executive Director	8.4yrs	CN¥96.91m	0.34% CN¥ 19.7m
Weichang Zhou	Honorary President of Global Biologics Development	9.2yrs	CN¥32.89m	0.012% CN¥ 666.6k
Ming Tu	CFO & Executive VP	2.6yrs	データなし	データなし
Lihua Yu	COO & Senior VP	less than a year	データなし	データなし
Sherry Gu	Chief Technology Officer and Executive VP of Global Biologics Development Department	less than a year	データなし	データなし
Jijie Gu	Chief Scientific Officer & President of Global Biologics Research	no data	データなし	データなし
Lina Fan	Senior VP & Head of Investor Relations	less than a year	データなし	データなし
Cong Ding	VP & Head of Legal Department	no data	データなし	データなし
He Wang	Chief Compliance Officer	1.8yrs	データなし	データなし
Li Xiong	VP & Head of Global Human Resources	no data	データなし	データなし
Angus Scott Turner	Senior VP and Head of Global BD & Alliance Management	no data	データなし	データなし

1.8yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: 1FW2の経営陣は経験豊富とはみなされません ( 1.8年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Ge Li	Founder & Chairman	10.3yrs	データなし	データなし
Zhisheng Chen	CEO & Executive Director	10.3yrs	CN¥96.91m	0.34% CN¥ 19.7m
Weichang Zhou	Honorary President of Global Biologics Development	8.1yrs	CN¥32.89m	0.012% CN¥ 666.6k
Jackson Tai	Independent Non-Executive Director	1.1yrs	CN¥710.00k	0.00062% CN¥ 35.5k
James Larrick	Member of Scientific Advisory Board	6.4yrs	データなし	データなし
David D. Ho	Member of Scientific Advisory Board	6.4yrs	データなし	データなし
Wei-Shou Hu	Member of Scientific Advisory Board	6.4yrs	データなし	データなし
Ram Sasisekharan	Member of Scientific Advisory Board	6.4yrs	データなし	データなし
William Robert Keller	Independent Non-Executive Director	7.1yrs	CN¥906.00k	0.00053% CN¥ 30.4k
Yanling Cao	Non-Executive Director	8.1yrs	データなし	データなし
Yibing Wu	Non-Executive Director	8.1yrs	データなし	データなし
Kenneth Walton Hitchner	Independent Non-Executive Director	4yrs	CN¥933.00k	0.0049% CN¥ 280.0k

6.8yrs

平均在職期間

59.5yo

平均年齢

経験豊富なボード: 1FW2の取締役会は経験豊富であると考えられます ( 6.8年の平均在任期間)。

WuXi Biologics (Cayman) マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

CEO & Executive Director recently sold €784k worth of stock

Less than half of directors are independent

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

Board Member recently sold €2.9m worth of stock

Recent updates

CEO & Executive Director recently sold €784k worth of stock

Investor sentiment deteriorates as stock falls 20%

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

Less than half of directors are independent

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P Global 1200

Investor sentiment deteriorates as stock falls 17%

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

Investor sentiment deteriorates as stock falls 16%

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

Investor sentiment deteriorates as stock falls 21%

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

Investor sentiment improves as stock rises 16%

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 32%

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

Board Member recently sold €2.9m worth of stock

Now 21% undervalued

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

First half 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.61 in 1H 2022)

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

Investor sentiment deteriorates as stock falls 22%

Now 23% undervalued after recent price drop

CEO & Executive Director recently sold €1.5m worth of stock

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes

Now 21% undervalued after recent price drop

Full year 2022 earnings released: EPS: CN¥1.06 (vs CN¥0.81 in FY 2021)

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

Investor sentiment improved over the past week

WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company

CEO & Executive Director recently sold €740k worth of stock

Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022.

WuXi Biologics (Cayman) Inc. Receives Regulatory Approvals for Drug Substance and Drug Product Facilities from U.S. FDA and EMA

Investor sentiment deteriorated over the past week

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0.44 in 1H 2021)

WuXi Biologics (Cayman) Inc. Appoints Weichang Zhou as Member of the Strategy Committee

Now 21% undervalued

WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022

Now 21% undervalued

CEO & Executive Director recently sold €2.1m worth of stock

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: CN¥0.81 (vs CN¥0.43 in FY 2020)

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Less than half of directors are independent

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14